Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Current Progress of Tissue Engineering With Stem Cells in Urology Updated Review in 2025

Kobayashi K., Horii T., Wada A., Yamanaka K., Hagiwara A., Kageyama S.

Narrative Review on Immune Modulation, published in Int J Urol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Int J Urol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40772396
PMCID
PMC12586785
DOI
10.1111/iju.70196
Citations
3

Abstract (original English)

Tissue engineering, a key component of regenerative medicine, aims to restore the structure and function of damaged organs using combinations of cells, scaffolds, and bioactive factors. In urology, the integration of stem cell biology has fueled significant progress in preclinical models for kidney, bladder, and urethral regeneration. Pluripotent stem cells, such as embryonic stem cells and induced pluripotent stem cells, offer broad differentiation potential, particularly in kidney organoid development. Meanwhile, multipotent stem cells-especially mesenchymal stem cells and urine-derived stem cells-have shown promise in bladder and urethral repair due to their immunomodulatory properties and relative ease of use. Despite these advancements, certain challenges remain: vascularization, functional integration, long-term safety, and scalability continue to limit the clinical application of regenerated organs. In kidney regeneration, issues such as nephron-collecting duct connectivity and urinary outflow remain unresolved. For the bladder and urethra, the need for vascularized, contractile, and innervated tissue complicates scaffold and cell selection. Nonetheless, clinical translation is becoming increasingly realistic. As the field evolves rapidly, it is essential for urologists to remain informed and actively engage in collaborative research. By integrating clinical expertise wi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
UrethraStem CellsAnimalsHumansUrologic DiseasesStem Cell TransplantationTissue EngineeringRegenerative MedicineUrologyRegeneration

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research